News Mixed outcomes for pharma in big week for FDA adcomms There was good news for Johnson & Johnson at this week's ODAC meetings, but not for Roche, UroGen, and Pfizer.
News J&J's 'Swiss army knife' drug gets first FDA approval Johnson & Johnson has its first regulatory approval for FcRn blocker Imaavy, getting a green light in the US for generalised myasthenia gravis (gMG).
News Data readout puts J&J's bladder cancer drug back on track New data in non-muscle-invasive bladder cancer (NMIBC) has backed up Johnson & Johnson's faith in its TAR-200 drug candidate.
News J&J expecting $400m hit from tariffs in 2025 J&J chief executive Joaquin Duato has told analysts that tax policy, not tariffs, is the key to increasing pharma manufacturing capacity in the US.
News At-home tablet now an option for NHS bladder cancer patients The first targeted drug for a common form of bladder cancer that can be taken at home. J&J's Balversa, has been backed for NHS use.
News Dexcom is first to join FDA/CMS health tech pilot The FDA has named Dexcom as the first company to take part in its TEMPO pilot, which aims to bring digital health tech to patients more quickly.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
